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concept derived from studies with genetically modified animal 
models. Thus, Ron DePinho and colleagues reported that onco-
genic H-Ras is essential for tumor maintenance in a doxycycline-
inducible H-RasV12G mouse melanoma model null for the tumor 
suppressor INK4a, as downregulation of the oncogene resulted in 
tumor regression (Chin et al., 1999). Moreover, Harold Varmus 
and coworkers developed transgenic mice expressing constitu-
tively active K-Ras under the control of doxycycline in type II 
pneumocytes. The induction of the oncogene led to development 
of lung adenocarcinomas, which underwent apoptotic regression 
upon removal of the inductor, demonstrating that the function 
of this oncogene is necessary to maintain the viability of tumor 
cells even in the absence of key tumor suppressors such as p53 or 
Ink4A (Fisher et al., 2001). Similar approaches revealed the role 
of myc in the maintenance of tumors initiated by this oncogene 
in transgenic animals. In this regard, Felsher and Bishop (1999) 
reported that a myc transgene expressed in hematopoietic cells 
caused malignant T cell leukemias and acute myeloid leukemias, 
while switching off oncogene expression caused differentiation, 
proliferative arrest, and apoptosis of the leukemia cells. The role of 
myc in the maintenance of myc-driven skin premalignant lesions 
as well as invasive pancreatic tumors in transgenic mice was also 
reported (Pelengaris et al., 1999, 2002). Finally, tetracycline-regu-
lated expression of a BCR–ABL transgene allowed demonstrating 
its role in the maintenance of leukemia initiated by this fusion 
oncogene in mice (Huettner et al., 2000).
However, the best validation of the oncogene addiction con-
cept came from the success obtained with a few anti-cancer agents 
directed against the proteins encoded by the driver oncogenes of 
particular cancer types. Even though the number of such molecu-
larly targeted therapies is low and their clinical benefits still limited, 
these therapies have improved the survival of patients suffering 
some previously intractable cancers (Haber et al., 2011). Well-
known cases of oncogenes clinically targeted with either  humanized 
Progression from normalcy to malignancy results from the acquisi-
tion of several fundamental changes in cellular behavior, which in 
turn derive from the accumulation of a large number of genetic and 
epigenetic changes (Galluzzi et al., 2011; Hanahan and Weinberg, 
2011). A few of the genetic alterations present in a cancer cell are 
essential for the development of the cancer phenotype (driver muta-
tions) and are accompanied by a much larger number of incidental 
passenger mutations that do not contribute directly to oncogenesis 
but still may have an impact on the biology of the tumor cells 
(Haber and Settleman, 2007). The heterogeneous arrangement 
of molecular abnormalities present in cancer cells gives rise to a 
complex and largely unpredictable scenario of interwoven altera-
tions in signaling and metabolic pathways (Wood et al., 2007). The 
multiple genetic interactions taking place at the cancer genome are 
responsible for the biological resilience of tumor cells, but also for 
specific weaknesses which, if appropriately exploited, could provide 
valuable targets of therapeutic intervention (Ashworth et al., 2011).
Cancer therapy is based on the increased susceptibility of tumor 
cells and tissues to different agents. Drugs traditionally used for 
cancer treatment present anti-tumor effect due to their preferential 
action against rapidly proliferating cells. Despite the large amount 
of resources invested in the development of novel drugs and in 
the optimization of administration schemes, these approaches are 
limited by the lack of specificity, which often results in unacceptable 
toxicity, and the evolution of the cancer cell population to eventu-
ally become resistant to the treatment.
OncOgene addictiOn
In line with the multiple efforts to develop more efficient and 
selective therapies based on targeting tumor-specific traits, the 
concept of “oncogene addiction” was introduced to emphasize 
the apparent dependency of cancer cells on one or a few genes 
for the maintenance of the malignant phenotype (Weinstein, 
2002; Weinstein and Joe, 2006, 2008). Important support for this 
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response to overload this stress defense system. Analogously, the 
taxanes used for the treatment of breast and ovarian cancers cause 
an overload of mitotic stress by interfering with proper spindle–
kinetochore attachment (Jordan and Wilson, 2004). However, 
the concept of non-oncogene addiction did not play a significant 
role in the development of these therapies. Recently, the direct 
involvement of several proteins in this phenomenon has been 
reported. In this regard, one of the best examples of non-oncogene 
addiction factors is represented by HSF1 (heat shock factor 1), an 
evolutionary conserved transcription factor that coordinates the 
heat shock response in eukaryotes and protects the cell against 
protein misfolding and aggregation. HSF1 is required for tumor 
initiation and maintenance in a variety of cancer models, and in 
consequence it has been proposed to represent a promising drug 
target (Dai et al., 2007). Also involved in cell protection against 
unfolded protein stress, heat shock protein 70 (HSP70) has been 
shown to be inhibited by small molecules with anti-cancer effects 
in preclinical models (Galluzzi et al., 2009; Leu et al., 2009), further 
illustrating the relevance of protein homeostasis for the develop-
ment of new anti-cancer therapies. Also, the transcription factor 
interferon regulatory factor 4 (IRF4), which maintains the expres-
sion of the MYC oncogene through an autoregulatory circuit, has 
been reported to be essential for myeloma cells independently of 
their transforming oncogenic mechanisms, constituting another 
paradigmatic example of non-oncogene addiction factor (Shaffer 
et al., 2008).
Synthetic lethality in cancer
The potential of non-oncogene addiction as basis of anti- 
cancer therapies relies on the identification of the putative fac-
tors involved in this process. Thus, investigating the genetic 
interactions taking place in cancer biology both in vivo and in 
experimental settings can result in the identification of new 
therapeutic targets and strategies. This idea has fueled a number 
of synthetic lethality screens. The concept of synthetic lethality 
derives from classical genetic studies and refers to the interac-
tion among two genes in which alterations in any of them are 
compatible with cell or organism viability, while the combina-
tion of defects in both genes causes lethality or fitness impair-
ment (Kaelin, 2005; Chan and Giaccia, 2011). Synthetic lethal 
targeting of cancer cells provides a genotype-selective approach 
as only the cancer cells with alterations in specific genes or 
pathways are sensitive to the therapy and, at the same time, it 
allows to exploit cancer alterations that are difficult to target 
directly. Consequently, a number of studies have used synthetic 
lethal screens for identifying new anti-cancer drugs. Some of 
these studies have compared the activity of collections of chemi-
cal compounds on isogenic cell lines with and without specific 
genetic alterations. Alternatively, genetic screens of synthetic 
lethality can be performed using siRNA or shRNA libraries to 
identify genes whose knockdown is preferentially harmful to 
the cells carrying a defined molecular defect. So far, the most 
successful application of the synthetic lethality concept in anti-
cancer research has led to the discovery and development of 
poly(ADP-ribose) polymerase (PARP) inhibitors to treat cancers 
with BRCA1 or BRCA2 mutations (Bryant et al., 2005; Farmer 
et al., 2005; Rehman et al., 2010). Other studies have pursued 
monoclonal antibodies or small-molecule inhibitors include HER2 
in breast cancer (Eisenhauer, 2001), EGFR and ALK in non-small 
cell lung cancer (Kwak et al., 2010; Maemondo et al., 2010), BCR–
ABL in chronic myeloid leukemia (Peggs and Mackinnon, 2003), 
KIT in gastrointestinal stromal tumor (Heinrich et al., 2003), or 
B-RAF in metastatic melanoma (Flaherty et al., 2010), among 
others.
These results strongly support the notion that oncogenic altera-
tions are required both for tumor establishment and maintenance 
and therefore, at least in theory, represent optimal anti-cancer drug 
targets (Sharma and Settleman, 2007). Despite the tremendous 
significance of this concept, the complexity of the mutational 
landscape of human cancers limits its practical application, as 
large-scale sequencing approaches have revealed that most tumors 
harbor diverse combination of low-frequency mutations rather 
than one or a few frequently mutated oncogenes as drivers of the 
neoplastic phenotype (Wood et al., 2007; Diamandis et al., 2010). 
Besides, some of the most prevalent tumorigenic genetic altera-
tions do not yield easily targetable products. This is the case for 
most loss of function mutations in tumor suppressor genes, but 
also for many oncogenes such as the members of the Ras family, 
in which activating mutations do not involve the acquisition of a 
new or exacerbated catalytic activity, making oncogene addiction 
difficult to exploit therapeutically.
nOn-OncOgene addictiOn
A growing body of evidence has demonstrated that there are many 
proteins which, even without undergoing activating mutations, 
are critical for tumor development and maintenance. This fact led 
to the introduction of the concept of “non-oncogene addiction” 
to define the exacerbated dependence of tumors on the normal 
function of certain genes which are not mutated oncogenes or 
tumor suppressors (Solimini et al., 2007). It has been proposed 
that non-oncogene addiction is based on the increased cellular 
stresses experienced by tumor cells as a side effect of the trans-
formed phenotype, such as DNA damage and replication, meta-
bolic or oxidative stress, and protein misfolding, making cancer 
cells more dependent on the respective stress support systems. 
Consequently, non-oncogene addiction provides a wide spectrum 
of potential therapeutic targets, whose inhibition could reverse the 
oncogenic phenotype, affecting the viability of normal cells at a 
lower degree. This goal can be achieved either by inhibiting the 
activity of the stress support mechanisms (stress sensitization) 
or through exacerbation of the existing oncogenic stress (stress 
overload; Solimini et al., 2007; Luo et al., 2009b). Tumor-intrinsic 
non-oncogene addiction factors act in a cell-autonomous fash-
ion, while tumor-extrinsic factors are required to provide stromal 
and vascular support to the tumor. The first group includes pro-
teins involved in protection against DNA damage and replicative 
stress, mitotic stress, proteotoxic stress, metabolic stress, oxidative 
stress, nutrient stress, hypoxia, and immune response modulation. 
Tumor-extrinsic factors include proteins regulating angiogenesis 
and stromal support.
Current cancer therapies often exploit non-oncogene addic-
tion-related phenomena to selectively kill cancer cells. For example, 
DNA-damaging agents and ionizing radiation take advantage of the 
genetic instability of cancer cells and their defects in DNA  damage www.frontiersin.org  September 2011  | Volume 1  |  Article 25  |  3
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PrOteOtOxic StreSS and PrOteaSOme addictiOn in 
cancer
Aneuploidy, copy-number variations and transcriptional alterations 
in cancer cells alter the dosage balance of components in protein 
complexes, causing proteotoxic stress and making cancer cells 
especially dependent on chaperone pathways as mentioned above, 
as well as on the cell machinery responsible for protein turnover. 
The responsibility for the degradation of unfolded proteins relies 
mainly in the ubiquitin–proteasome system, and consequently the 
proteolytic enzymes acting in this system are potential candidates 
for pharmacological targeting (Bedford et al., 2011). The therapeutic 
potential of this degradative pathway has been demonstrated by the 
development of bortezomib, an inhibitor of the 26S proteasome 
used for the treatment of myeloma and mantle cell lymphoma. 
Bortezomib is a peptide boronic acid that inhibits the proteasome 
by binding to its chymotrypsin-like site. Bortezomib induces apo-
ptosis of cancer cells through mechanisms that probably include 
stabilization of proapoptotic proteins, inhibition of NF-κB function 
and interference with the unfolded protein response, causing endo-
plasmic reticulum stress. Besides, some of the anti-cancer effects of 
bortezomib seem to be due to alterations of the microenvironment 
and angiogenesis inhibition (Adams, 2004; Navon and Ciechanover, 
2009). Remarkably, bortezomib shows additive effects with other 
therapies in several experimental models, chemosensitizing cancer 
cells to radiation therapy or to drugs such as doxorubicin, irinote-
can, gemcitabine, cyclophosphamide, or cisplatin (Adams, 2004), 
supporting the synergistic effect of the stress overload and stress 
sensitization anti-cancer approaches discussed above. The turnover 
of cancer-relevant proteins in the proteasome can also be targeted 
indirectly through the inhibition of E3 ubiquitin ligases. In this 
regard, the inhibition of members of the cullin–RING subfamily 
has shown promise against cancer (Soucy et al., 2009). Moreover, 
the possibility of specifically targeting the activity of individual 
the identification of compounds and genes synthetically lethal 
with genetic alterations in other tumor suppressors such as VHL 
or PTEN as well as in oncogenes such as RAS or MYC, leading 
to the identification of several non-oncogene addiction factors 
differentially essential for the cancer cells carrying these par-
ticular alterations (Chan and Giaccia, 2011).
PrOteaSe addictiOn
Proteolytic enzymes play a large variety of critical roles in the regula-
tion and execution of most physiological processes and pathological 
conditions (Lopez-Otin and Bond, 2008) acting frequently through 
a complex crosstalk with other important regulators of cell biology 
such as protein kinases and phosphatases (Lopez-Otin and Hunter, 
2010). Consequently, the potential of tumor proteases as targets of 
anti-cancer therapies has been frequently explored (Overall and 
Lopez-Otin, 2002). The success of some of these attempts was lim-
ited by the overwhelming complexity of the human degradome (the 
repertoire of proteolytic enzymes, substrates, and inhibitors) and 
by the fact that some proteases are important players in the natural 
anti-cancer defenses rather than being cancer-promoting enzymes 
(Lopez-Otin and Matrisian, 2007). However, a wide diversity of 
proteases are involved in physiological mechanisms such as those 
responsible for the protection against most if not all the above 
discussed cancer-associated stresses. Moreover, the mechanisms of 
action of proteases have been the subject of innumerable studies 
over many decades and are probably the best known among all 
enzymatic activities, facilitating the development of specific inhibi-
tors (Turk, 2006). Consequently, we hypothesize that most if not 
all tumors present “addiction” to a number of proteolytic activi-
ties, which in turn may represent valuable targets of anti-cancer 
therapies, even without being mutated or over-expressed by the 
malignant cells (Figure 1). Below we discuss briefly a few examples 
supporting this proposal.
Figure 1 | Protease addiction in cancer. Cancer cells are under different forms of cellular stress as a side effect of the transformed phenotype. We hypothesize 
that for most cases of cancer, it will be possible to find one or more proteases specifically required for the maintenance of cancer cell viability.Frontiers in Oncology | Molecular and Cellular Oncology    September 2011  | Volume 1  |  Article 25  |  4
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Synthetic lethality Of PrOteaSeS with OncOgeneS 
and tumOr SuPPreSSOr geneS
Considering the overwhelming diversity of functions played by 
proteases, it seems reasonable to expect that one or more proteo-
lytic enzymes will be involved in synthetic lethality interactions 
with most oncogenes and tumor suppressor genes (Figure 2). In 
our opinion, the results derived from several large-scale synthetic 
lethality screens carried out with some of the most relevant onco-
genes support this hypothesis. The RNAi-based genome-wide 
screen performed by Stephen Elledge’s group with KRAS provides 
one of the best examples in this regard (Luo et al., 2009a). These 
authors discovered a set of genes whose silencing was preferentially 
lethal for cancer cells carrying activating KRAS mutations due to 
their exacerbated mitotic stress. The Ras synthetic lethal factors 
identified in this study included the Polo-like kinase PLK1, the 
anaphase promoting complex/cyclosome (an E3 ubiquitin ligase 
that promotes the degradation of mitotic proteins) and, remark-
ably, the COP9 signalosome and the proteasome, among others. In 
agreement with the results of their RNAi screen, KRAS mutant cells 
are more sensitive to proteasome inhibitors such as bortezomib, 
providing pharmacological evidence of the protease addiction of 
these cancer cells (Luo et al., 2009a). Interestingly, Ras oncogenes 
also seem to involve another type of protease addiction: autophagy 
addiction, as cancer cells with activating mutations in these genes 
show hyperactivation of this degradative system, whereas down-
regulation of autophagy proteins causes growth impairment in a 
subset of these cells (Guo et al., 2011).
E3 enzymes opens new avenues in this field (Aghajan et al., 2010; 
Orlicky et al., 2010), widening the possibilities of exploiting pro-
teolytic addiction for cancer treatment.
taSPaSe addictiOn in cancer
Threonine aspartase 1 (taspase 1) is a threonine endoprotease 
that mediates the cleavage of intracellular proteins after aspar-
tate residues (Hsieh et al., 2003). Taspase 1 was first identified 
as the enzyme responsible for the cleavage of the mixed line-
age leukemia (MLL) protein, a proteolytic event which is cru-
cial for MLL stabilization and, in consequence, for proper HOX 
gene expression and MLL-mediated tumorigenesis (Hsieh et al., 
2003; Takeda et al., 2006). Taspase 1 is also over-expressed in 
solid tumors and acts on other regulatory proteins such as tran-
scription factor IIA (TFIIA) or DNA polymerase zeta (DPOLZ), 
among other substrates (Zhou et al., 2006; Knauer et al., 2011). 
Interestingly, taspase 1 has been reported to be required for in 
vitro transformation of mouse embryonic fibroblasts by diverse 
combinations of oncogene pairs (Takeda et al., 2006), but also to 
maintain the transformed phenotype of these cells (Chen et al., 
2010). Moreover, taspase 1 knockdown inhibited the prolifera-
tion of several human cancer cell lines and enhanced apoptosis, 
exhibiting a synergistic effect with chemotherapeutic agents at 
least in part through downregulation of the antiapoptotic protein 
MCL-1. These findings prompted Chen et al. (2010) to propose 
taspase 1 as a non-oncogene addiction protease with potential as 
a target of anti-cancer therapies.
Figure 2 | The concept of synthetic lethality applied to the interactions 
of proteases and cancer genes. Mutations in oncogenes and tumor 
suppressor genes act as drivers of neoplastic transformation. A protease is 
“synthetic lethal” with an oncogene or a tumor suppressor gene if its 
function is specifically indispensable for the survival of cells with mutations in 
those genes. Thus, a mutation in the protease-encoding gene or the 
pharmacological inhibition of the enzyme is tolerable for normal cells, but not 
for cancer cells.www.frontiersin.org  September 2011  | Volume 1  |  Article 25  |  5
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The identification of druggable proteins involved in synthetic 
lethality interactions with tumor suppressors can be of great 
potential for anti-cancer therapy, as brilliantly demonstrated by 
the development of PARP inhibitors to treat BRCA1/2-related 
cancers (Rehman et al., 2010). This possibility has been explored 
in a number of RNAi-based screens, but the identification of pro-
teases selectively required for the maintenance of cancer cells with 
mutations in particular tumor suppressors has been hampered by 
the limited RNAi libraries used in most of these studies (Bommi-
Reddy et al., 2008; Baldwin et al., 2010). It seems reasonable to 
assume that a more comprehensive exploration of the human 
degradome will allow the identification of targetable proteolytic 
enzymes. Remarkably, the work based on the results of a RNAi 
screen with a library targeting 2,287 genes (Lovejoy et al., 2009) 
led to the finding that ubiquitin specific protease 11 (USP11) par-
ticipates in repair of DNA double-strand breaks via homologous 
recombination. Silencing of this protease causes spontaneous DNA 
damage repair activation and hypersensitivity to PARP inhibition, 
ionizing radiation and other sources of genotoxic stress (Wiltshire 
et al., 2010). The synthetic lethal interaction between USP11 and 
PARP uncovered by this work illustrates the potential of proteases 
as critical players in maintaining cancer cell viability and high-
lights the special relevance of the ubiquitin–proteasome system 
in this regard.
cOncluSiOn and PerSPectiveS
Proteases have been regarded too often as demolition machines 
lacking the required finesse to be good candidate targets of anti-
cancer treatments. Fortunately, this view is changing dramatically. 
The extraordinary diversity of mechanisms of action used by 
the different proteases constituting the human degradome and 
the disparity of structural features underlying their functions, 
represent formidable challenges for the development of protease 
inhibitors but also provide a unique opportunity for synthesizing 
exquisitely selective compounds of potential anti-cancer inter-
est. According to the “cancer protease addiction” hypothesis that 
we put forward in this Perspective, it should be possible for any 
given tumor type to find proteolytic activities that are essential for 
cancer cell proliferation or survival, or whose inhibition could act 
synergistically with other therapies. We have discussed here a few 
examples of degradome members that represent good examples 
of protease addiction in different neoplastic contexts (Figure 3), 
but we have not attempted to provide a comprehensive cover-
age of this topic. Thus, we have not discussed some conspicu-
ous examples, such as gamma-secretase, a proteolytic complex 
required for Notch maturation and consequently a likely non-
oncogene addiction factor in neoplasias depending on this pro-
tein. Interestingly, gamma-secretase inhibitors have been reported 
to present a synergistic effect with glucocorticoids in leukemia 
cells (Real et al., 2009) and selectively target cancer stem cells in 
some neoplasias (Kondratyev et al., 2011), illustrating the diversity 
of the biological repercussions of targeting protease addiction for 
cancer treatment. Currently available data point to the ubiquitin–
proteasome system as the most promising source of druggable 
proteases for cancer treatment. The successful development of 
therapies based on proteasome inhibitors provides strong sup-
port to this idea and represents the most fruitful application of 
Other synthetic lethal screens with different oncogenes have 
been based on the use of non-genome-wide RNAi libraries, with 
a strong bias toward kinases among “cancer-relevant genes” and 
without representation of most members of the human degra-
dome. Nevertheless, additional examples of synthetic lethality of 
proteases with oncogenes have been found over the last few years. 
Thus, Bivona et al. (2011) carried out a screen with a shRNA 
library targeting approximately 2,000 cancer-related genes to 
identify proteins whose ablation rendered lung cancer cells sen-
sitive to EGFR inhibition. Interestingly, besides components of 
the FAS and NF-kB pathway, the list of proteins identified in 
this study includes PSMD14 (also known as POH1/RPN11), a 
deubiquitinating enzyme component of the proteasome that has 
been involved in regulation of the ErbB2 receptor (Liu et al., 
2009).
Besides the above discussed role of the ubiquitin–proteasome 
system in the protection of the cell against proteotoxic stress, 
this proteolytic system plays a critical role in the regulation of 
the cell cycle through the rapid turnover of regulatory proteins. 
In consequence, diverse components of this system are likely to 
be involved in non-oncogene addiction and synthetic lethality 
phenomena in different types of tumors. An interesting example 
of this possibility is represented by ubiquitin specific protease 
2 (USP2), a deubiquitinating enzyme from the USP family of 
cysteine proteases reported to stabilize cyclin D1. Cyclin D1 is 
an important regulator of the G1/S phase transition and is acti-
vated by chromosomal translocations or over-expressed in several 
cancer types. Shan et al. (2009) reported that USP2 specifically 
deubiquitinates and stabilizes cyclin D1, whereas knockdown of 
this protease causes cyclin D1 degradation and growth arrest in 
cancer cells dependent on this cell cycle regulator. Thus, the result-
ing non-oncogene addiction of these cancer cells to USP2 derives 
from its synthetic lethality with cyclin D1 and it could provide 
the rational to develop inhibitory compounds with anti-cancer 
potential.
Figure 3 | Functional interactions between proteases and cancer genes 
in the context of protease addiction processes in cancer. Several examples 
of proteolytic activities are shown in relation with different proteins involved in 
cancer development and survival, as discussed in the main text.Frontiers in Oncology | Molecular and Cellular Oncology    September 2011  | Volume 1  |  Article 25  |  6
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